PRESCRIPTION AUDIT AND EFFECTS OF COMORBIDITIES ON INDOOR COVID-19 PATIENTS OF A TERTIARY CARE TEACHING HOSPITAL
DOI:
https://doi.org/10.22159/ajpcr.2024.v17i5.49995Keywords:
Prescription audit, Comorbidity, COVID-19Abstract
Objective: Management of COVID-19 has been a challenge to the health-care system. The COVID-19 pandemic led to prescribing a greater number of drugs for curing the disease in the initial phase of the pandemic due to a lack of understanding of the pathophysiology of COVID-19, symptomatic treatment was given as no definite treatment was available. This presented an opportunity to assess prescribing practices during the pandemic.
Methods: The study presents a retrospective cohort to assess 300 random prescriptions from indoor COVID-19 patients of a tertiary care teaching hospital. The parameters analyzed in the process of the prescription audit were patients’ demographics data, prescribing standards according to the World Health Organization core indicators, clinical diagnosis with the comorbid condition, legibility of handwriting, doctor’s name and signature, and outcome of the disease.
Results: Out of 300 cases analyzed, a total of 298 (99.66%) prescriptions were with antimicrobialsa total of 55 (18.3%) patients received antivirals. 167 (55.67%) admitted patients having comorbidities such as hypertension (28%) and diabetes (24.3%).
Conclusion: It is observed almost every patient has received antimicrobial in the form of antibiotic or antiviral. About 18.3% of patients received antiviral drugs. The effect of co-morbidity has a significant influence on the outcome of patients having COVID-19, as in this study, mortality rate in diabetic patients is higher up to 11.48% than in non-diabetics.
Downloads
References
World Health Organization. WHO Coronavirus Disease [COVID-19] Dashboard; 2022. Available from: https://covidig.who.int [Last accessed on 2023 Dec 23].
Treatment Covid 19 Guidelines. Available from: https://files. covid19treatmentguidelines.nih.gov/guidelines/archive/covid19
World Health Organization. How to Investigate Drug use in Health Facilities: Selected Drug use Indicators-EDM Research Series No 007.1993. Available from: https://www.apps.who.int/medicinedocs/ en/d/Js2289e
Available from: https://apps.who.int/iris/bitstream/ handle/10665/349321/who-2019-ncov-clinical-2021.2-eng.pdf
Dagli RJ, Sharma A. Polypharmacy: A global risk factor for elderly people. J Int Oral Health. 2014;6(6):i-ii. PMID 25628499
WHO. Report HT. A Glossary of Terms for Community Health Care and Services for Older Persons. Vol. 5. Geneva: World Health Organization; 2004. p. 45.
Callender LA, Curran M, Bates SM, Mairesse M, Weigandt J, Betts CJ. The Impact of pre-existing comorbidities and therapeutic interventions on COVID-19. 2020;11:1991.
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical consideration. Diabetes Metab Syndr. 2020;14(4):303-10. doi: 10.1016/j. dsx.2020.04.004, PMID 32298981
Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31(6):1068-77.e3. doi: 10.1016/j.cmet.2020.04.021, PMID 32369736
Yu T, Du R, Fan G, Liu Y, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-62. doi: 10.1016/S0140-6736(20)30566-3, PMID 3217107611. Sun F, Kou H, Wang S, Lu Y, Zhao H, Li W, et al. An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients. Ann Transl Med. 2021;9(4):306. doi: 10.21037/atm-20-4960
Mandal SK, Neupane J, Kumar AM, Davtyan H, Thekkur P, Jayaram A, et al. Audit of clinical care received by COVID-19 patients treated at a tertiary care hospital of Nepal in 2021. Trop Med Infect Dis. 2022;7:381. doi: 10.3390/tropicalmed7110381
Gawali UP, Gurung A. Study of drug utilization pattern during second wave of Covid-19 in a tertiary care centre: A retrospective cross-sectional study. J Pharm Care. 2022;10(4):211-7. doi: 10.18502/jpc.v10i4.11581
Published
How to Cite
Issue
Section
Copyright (c) 2024 Shahenaz Malek, Dr. Amita Kubavat, Dr. Anil Singh, Dr. Pratik Chabhadiya , Dr. Dwija Rajguru, Dr. Hetav Purohit, Dr. Karan Hajare, Dr. Taksh Hadvani
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
